Enveric Biosciences (ENVB) EBIT Growth (3y) (2013 - 2026)
Enveric Biosciences (ENVB) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 69.02% |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 24.14% |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 44.54% |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 44.34% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -28.30% |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 81.27% |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | -18.82% |
| 10 | Enveric Biosciences | 5.62 Mn | -2.67 Mn | - | 19.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.48% |
| Dec 31, 2025 | 43.64% |
| Sep 30, 2025 | 30.81% |
| Jun 30, 2025 | 18.81% |
| Mar 31, 2025 | 23.02% |
| Dec 31, 2024 | 60.37% |
| Sep 30, 2024 | 16.02% |
| Jun 30, 2024 | 17.36% |
| Mar 31, 2024 | 28.46% |
| Dec 31, 2023 | 12.20% |
| Sep 30, 2023 | -91.66% |
| Jun 30, 2023 | -95.73% |
| Mar 31, 2023 | -79.77% |
| Dec 31, 2022 | -99.98% |
| Sep 30, 2022 | -53.47% |
| Jun 30, 2022 | -47.18% |
| Mar 31, 2022 | -54.58% |
| Dec 31, 2021 | -67.74% |
| Sep 30, 2021 | -37.09% |
| Jun 30, 2021 | -46.05% |